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Psoriasis and Osteoporosis: A Sex-Specific
Association?
Jacob Dreiher1,2, Dahlia Weitzman3 and Arnon D. Cohen2,4
Previous reports showed associations between psoriasis and chronic diseases. Little is known about the
association between osteoporosis and psoriasis. The goal of the study was to assess the association between
psoriasis and osteoporosis in a population-based case–control study, utilizing the database of a large health-care
provider organization in Israel, Clalit Health Services. Patients (aged 51–90 years) diagnosed with psoriasis were
compared with a sample of age- and sex-matched enrollees without psoriasis regarding the prevalence of
osteoporosis. Data on health-related lifestyles and other comorbidities were collected. The study included 7,936
psoriasis cases and 14,835 controls. The prevalence of osteoporosis was significantly greater in males with
psoriasis compared with the control group (3.1 vs 1.7%, Po0.001, odds ratio (OR)¼ 1.86, 95% confidence interval
(CI): 1.44–2.39) and slightly greater in females with psoriasis (22.3 vs 20.2%, P¼ 0.008, OR¼ 1.13, 95% CI: 1.03–1.25).
A multivariate logistic regression model demonstrated that after controlling for confounders, psoriasis was
significantly associated with osteoporosis in males (adjusted OR¼ 1.70, 95% CI: 1.31–2.19, Po0.001). The weak
association between psoriasis and osteoporosis in females lost statistical significance in a multivariate model
(adjusted OR¼ 1.09, 95% CI: 0.98–1.21, P¼ 0.100). Psoriasis was found to be associated with osteoporosis among
males, but not among females.
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INTRODUCTION
Psoriasis is a chronic inflammatory disease of the skin that is
prevalent in the general population (2–4%) (Langley et al.,
2005; Scho¨n and Henning-Boehricke, 2005). Recent
evidence shows that psoriasis is associated with complex
chronic comorbidity (Naldi et al., 2005; Gelfand et al., 2006;
Mallbris et al., 2006; Neimann et al., 2006; Sterry et al.,
2007; Wakkee et al., 2007). Psoriasis is associated with
markers of systemic inflammation and a high frequency of
cardiovascular events, diabetes, and dyslipidemia (Naldi
et al., 2005; Gelfand et al., 2006; Mallbris et al., 2006;
Neimann et al., 2006; Sterry et al., 2007; Wakkee et al.,
2007).
Osteoporosis is defined as a reduction in bone mass and
disruption of the microarchitecture of bone, resulting in
decreased bone strength leading to an increased risk of
fractures (Poole and Compston, 2006; Lindsay and Cosman,
2008). The World Health Organization defines osteoporosis
as a bone mineral density (BMD) that falls 2.5 standard
deviations below the mean for young healthy adults of the
same sex, whereas T scores between 2.5 and 1 standard
deviations are defined as osteopenia (WHO, 1994). Common
locations for osteoporotic fractures are the spine, hip, wrist,
humerus, and pelvis. Hip fractures result in the loss of
independence for at least one-third of people with osteo-
porosis, and vertebral fractures cause height loss, chronic
pain, and difficulty with normal daily activities (Poole and
Compston, 2006).
Osteoporosis occurs more frequently in women than in
men, particularly postmenopausal women, and is more
common with increasing age. Age-related bone loss starts
in the fourth or fifth decade of life. In women, the loss of
ovarian function at menopause (around age 50 years) results
in rapid bone loss due to estrogen deficiency (Poole and
Compston, 2006; Lindsay and Cosman, 2008). Osteoporosis
is an under-recognized problem in men, and it is untreated in
the majority of men with fractures (Ebeling, 2008). Bone mass
in elderly men is also positively related to estrogen levels.
Genetic factors have a strong influence on peak bone mass
attained during the third decade of life, which is an important
determinant of bone mass later in life. Nutritional factors,
including calcium and vitamin D intake, hormonal status,
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and physical activity, also influence peak bone mass (Poole
and Compston, 2006). Vitamin D deficiency and secondary
hyperparathyroidism are common in elderly people.
Additional risk factors include cigarette smoking, alcohol
consumption, and reduced physical activity, as well as
chronic inflammatory diseases, malabsorption states, hypo-
gonadism, endocrine disorders, severe liver disease,
rheumatoid arthritis, ankylosing spondylitis, hematological
malignancies, chronic obstructive pulmonary disease,
sarcoidosis, amyloidosis, multiple sclerosis, and other rare
diseases (Poole and Compston, 2006; Ebeling, 2008; Lindsay
and Cosman, 2008).
Recent advances in understanding the pathogenesis of
osteoporosis shed light on the role of various cytokines,
including IFN-g, IL-6, and tumor necrosis factor (TNF-a) in
osteoporosis (Raisz, 2005; Duque and Troen, 2008; Lindsay
and Cosman, 2008; Tilg et al., 2008). The same cytokines
appear to be active in the pathogenesis of psoriasis as well
(Hofbauer et al., 2006; Kastelan et al., 2006).
In previous studies, we have described the association
between psoriasis and other diseases including diabetes
(Shapiro et al., 2007) and chronic obstructive lung disease
(Dreiher et al., 2008). The purpose of this study was to assess
the association between psoriasis and osteoporosis utilizing
the large medical dataset of Clalit Health Services (CHS).
RESULTS
The study initially included 12,405 psoriasis cases and
24,096 age- and sex-matched controls aged 20–90 years. As
the prevalence of osteoporosis was very low in those younger
than 51 years (49/12,929¼0.4%), we focused on patients
older than 51 years. The final sample included 7,936 cases
and 14,835 controls. Despite matching, psoriasis cases were
slightly older (mean age: 65.6 vs 65.2, P¼ 0.003) and were
more likely to be male (51.8 vs 48.7%, Po0.001). Psoriasis
patients were more frequently diagnosed with other diseases
and unhealthy lifestyles, some of which are associated with
osteoporosis (Table 1). Of 109 chronic diagnoses included in
the database, 56 were significantly more prevalent among
cases as compared with controls (Po0.05 in a univariate
analysis). Overall, in addition to psoriasis, cases had 5.0±3.3
chronic diagnoses, whereas controls had 3.7±3.0
(Po0.001). Psoriasis patients were significantly more likely
to be treated with acitretin. No difference in other medica-
tions, including anti-TNF-a, IFN-a, and azathioprine, was
noted (Table 1). None of these medications, including
acitretin, was associated with osteoporosis (data not shown).
Overall, osteoporosis was diagnosed among 12.4% of
cases, compared with 11.2% of controls (P¼0.007; odds
ratio (OR)¼ 1.12, 95% confidence interval (CI): 1.03–1.22).
As the mechanisms underlying osteoporosis are quite
different in men and women, we analyzed the association
between psoriasis and osteoporosis separately by sex.
Among males, the prevalence of osteoporosis was
significantly higher among cases than among controls (3.1
vs 1.7%, Po0.001, respectively; OR¼1.86, 95% CI:
1.44–2.39). We performed a stratified analysis in various
subgroups (Tables 2 and 3). The prevalence increased
with age in both cases and controls, but the strength of the
association decreased with increasing age (Table 2). Thus,
a statistically significant effect modification by age
was observed (P¼0.006 for effect modification). Blindness
was also found to be an effect modifier of the
association (P¼0.01 for effect modification). Analysis of
the association between psoriasis and osteoporosis in males
with and without known risk factors for osteoporosis is listed
in Table 2.
Among females, the prevalence of osteoporosis was much
greater than in males, and only slightly greater among cases
than among controls (22.3 vs 20.2%, respectively; P¼0.008,
OR¼1.13, 95% CI: 1.03–1.25). The prevalence increased
with age in both cases and controls. Only in women older
than 80 years psoriasis was significantly associated with
osteoporosis (Table 3). A stratified analysis for additional risk
factors appears in Table 3.
A multivariate logistic regression model demonstrated that
among males, psoriasis was associated with osteoporosis
even after controlling for confounders, including age, the
presence of inflammatory bowel disease, and the number of
chronic diagnoses (OR¼1.35, 95% CI: 1.04–1.75, P¼0.024,
Table 4). Among females, the weak association lost statistical
significance in the multivariate model, after controlling for
various confounders (OR¼0.90, 95% CI: 0.80–1.00,
P¼0.049, Table 5).
Table 1. Baseline characteristics of the study
population (N=22,771)
Characteristic
Psoriasis patients
(n=7,936)
Controls
(n=14,835) P-value
Age (years): mean±SD 65.6±10.1 65.2±10.2 0.003
Median 64 63
Range 51–90 51–90
Male 4,113 (51.8%) 7,231 (48.7%) o0.001
Inflammatory bowel
disease
70 (0.9%) 78 (0.5%) 0.001
Chronic hepatitis 116 (1.5%) 74 (0.5%) o0.001
Rheumatoid arthritis 346 (4.4%) 139 (0.9%) o0.001
Chronic obstructive lung
disease
653 (8.2%) 795 (5.4%) o0.001
Blindness 90 (1.1%) 113 (0.8%) 0.004
Depression 712 (9.0%) 884 (6.0%) o0.001
Hypothyroidism 867 (10.9%) 1,243 (8.4%) o0.001
Obesity 2,330 (29.4%) 2,989 (20.1%) o0.001
Osteoporosis 982 (12.4%) 1,659 (11.2%) 0.007
Anti-tumor necrosis
factor-a
2 (0.02%) 3 (0.02%) 1.000
IFN-a 10 (0.1%) 21 (0.1%) 0.763
Acitretin 9 (0.1%) 0 o0.001
Azathioprine 8 (0.1%) 7 (0.1%) 0.133
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DISCUSSION
This study is a population-based case–control study, based on
a large sample of patients with psoriasis and controls from the
CHS database. Psoriasis was found to be associated with a
greater prevalence of osteoporosis among males, an associa-
tion that was somewhat attenuated after controlling for
potential confounders. In contrast, the association between
psoriasis and osteoporosis among females was rather
weak, and lost statistical significance after controlling for
confounders.
Our understanding of the pathogenesis of osteoporosis has
improved recently. Bone remodeling is regulated by both
systemic hormones (estrogens, androgens, vitamin D, and
parathyroid hormone) and locally produced factors (trans-
forming growth factor-b, parathyroid hormone-related pep-
tide, ILs, and TNFs). Several factors, including IL-1, IL-6,
IL-11, parathyroid hormone, thiazolidinediones, and TNF, are
known to promote bone damage, whereas others (estrogens,
calcitonin, transforming growth factor-b, platelet-derived
growth factor, IL-17, and mechanical force) aid bone repair
(Duque and Troen, 2008; Lindsay and Cosman, 2008). Three
members of the TNF and TNF receptor superfamily are
involved. Hematopoietic cells bear the receptor activator of
NF-kB (RANK). Osteoblasts produce RANK ligand (RANKL),
which activates the differentiation of osteoclasts and main-
tains their function. Osteoblasts also produce and secrete
osteoprotegerin, a decoy receptor that can block RANK–-
RANKL interactions. Stimulators of bone resorption increase
RANKL expression in osteoblasts, and some also increase
osteoprotegerin expression. Osteoclast activation may there-
fore be initiated by inflammatory cells, particularly T cells
(Raisz, 2005; Tilg et al., 2008) TNF-a is the key pro-
inflammatory cytokine that directly and indirectly promotes
inflammation-associated osteoporosis. IL-1b enhances osteo-
clastogenesis in the presence of permissive levels of RANKL.
IL-6 is a cytokine of the acute-phase response. Neutralizing
anti-IL-6 antibodies inhibit osteoclast formation. IFN-g causes
bone loss, in particular by enhancing T cell activation. IFN-g
can also inhibit osteoclastogenesis when directly acting on
developing osteoclasts (Tilg et al., 2008).
These mechanisms suggest that osteoporosis could be
considered an immunological disorder. Clinical observations
reveal colocalization of regional inflammation, as well as
coincidence of systemic osteoporosis with periods of
systemic inflammation. Old age is characterized by an
acceleration of diseases that are increasingly attributed to
inflammation. Cytokines such as IL-6, TNF-a, and IL-1 are
elevated during senescence and play direct roles in the
pathogenesis of these diseases (De Martinis et al., 2006).
Some reports show direct correlation between serum
osteoprotegerin, cytokine levels, and disease activity in
several inflammatory disorders, including rheumatoid arthri-
tis, primary biliary cirrhosis, and inflammatory bowel disease
(Rodriguez-Bores et al., 2007).
Several mechanisms for the apparent association between
psoriasis and osteoporosis can be suggested. Psoriasis is a
chronic inflammatory state (Langley et al., 2005) and chronic
inflammation might be an important component in the
pathogenesis of osteoporosis. Cytokines related to osteoporo-
sis play a major role in psoriasis. T lymphocytes affect
epidermal growth homeostasis by inducing increased
keratinocyte proliferation and abnormal differentiation.
Activation of T cells is a key step in psoriasis. Psoriasis is
characterized by the Th-1 type cytokine pattern with the
predominant secretion of IL-2, IL-6, IFN-g, and TNF-a. Some
of these cytokines are produced by keratinocytes, rather
than by T cells (Langley et al., 2005; Scho¨n and
Henning-Boehricke, 2005; Kastelan et al., 2006).
Most studies on the association between psoriasis and
osteoporosis (Nymann et al., 1996; Millard et al., 2001;
Borman et al., 2008) included few patients. Osteoporosis has
been linked to palmoplantar pustular psoriasis (Nymann
et al., 1996), but not to chronic plaque psoriasis (Millard
et al., 2001), although patients with psoriatic arthritis had
lower BMD. Hofbauer et al. (2006) evaluated BMD as well as
cytokine levels related to bone remodeling in psoriatic
arthritis. Osteopenia was found in 35% of women and 31%
of men with psoriatic arthritis; osteoporosis was detected in
one woman (1.8%) and six men (10.2%). Psoriatic arthritis
patients had similar osteoprotegerin levels, but higher levels
of TNF-related apoptosis-inducing ligand (Hofbauer et al.,
2006). In another study, no significant difference between
psoriasis patients with and without arthritis was found,
although both groups had BMD below that of age-matched
controls. In the arthritis group, one patient (5%) had
osteoporosis and nine (50%) had osteopenia (Borman et al.,
2008). In the group without arthritis, none had osteoporosis
and eight (27.5%) had osteopenia. A study from Sweden
(Osmancevic et al., 2008) reported a greater BMD at the hip
among women with psoriasis treated with UVB than among
controls; no differences in BMD values at the spine were
noted. The greater BMD was attributed to a higher body
weight and UVB therapy, which replenishes vitamin D in the
skin of patients in this Scandinavian country, in which sun
exposure in winter is minimal. This difference probably does
not play a major role in this study, conducted in a sunny
country like Israel. Some studies found BMD values similar to
healthy controls among patients with psoriatic arthritis (Grisar
et al., 2002), whereas others reported lower BMD (Frediani
et al., 2001; Millard et al., 2001). It has been hypothesized
that psoriasis is related to an increased risk of osteoporosis
due to enhanced activity of IL-6 and TNF-a (Kastelan et al.,
2006). Additional explanations linking psoriasis with osteo-
porosis might include a lack of physical activity, smoking,
and alcohol consumption, which are known risk factors for
osteoporosis (Poole and Compston, 2006; Duque and Troen,
2008; Lindsay and Cosman, 2008), and are common in
patients with psoriasis (Naldi et al., 2005). Topical corticos-
teroids are not considered to be sufficiently absorbed to the
extent of increasing the risk of osteoporosis, although they
have been shown to be associated with other metabolic
disorders, such as diabetes mellitus.
It is of interest to note that the association between
psoriasis and osteoporosis in this study was significant only
among men. Similar to previous studies, osteoporosis was
much more common in women. Osteoporosis among women
www.jidonline.org 1645
J Dreiher et al.
Psoriasis and Osteoporosis
is usually the result of estrogen deficiency, and menopause
seems to be a stronger risk factor for osteoporosis than
psoriasis. In contrast, osteoporosis in males is more
commonly the result of a systemic disease, which in this
case was found to be psoriasis. Alternatively, as women are
more likely to be routinely referred to BMD scans, men
diagnosed with osteoporosis are more likely to represent a
chronically ill population. Similarly, the association between
psoriasis and osteoporosis among males was not statistically
significant above the age of 80 years, probably because in
this subgroup, age is a stronger risk factor for osteoporosis
than psoriasis.
This study has some potential limitations. Directionality of
the association cannot be established with certainty. We had
Table 2. Stratified analysis of the association between psoriasis and osteoporosis among males (N=11,344)
Subgroups N OP in psoriasis cases (n=4,113) OP in controls (n=7,231) OR (95% CI)
All 11,344 128 (3.1%) 123 (1.7%) 1.86 (1.44–2.39)2
Age (years)
51–60 4,844 38 (2.3%) 20 (0.6%) 3.66 (2.12–6.32)2
61–80 5,417 72 (3.5%) 72 (2.1%) 1.66 (1.19–2.32)2
81–90 1,083 18 (4.6%) 31 (4.5%) 1.04 (0.57–1.89)
IBD
Without IBD 11,261 124 (3.0%) 117 (1.6%) 1.90 (1.47–2.46)2
With IBD 83 4 (9.8%) 6 (14.3%) 0.65 (0.16–2.50)
Chronic hepatitis
Without hepatitis 11,250 125 (3.1%) 121 (1.7%) 1.86 (1.44–2.40)2
With hepatitis 94 3 (4.8%) 2 (6.3%) 0.76 (0.12–4.82)
RA
Without RA 11,205 119 (3.0%) 122 (1.7%) 1.77 (1.37–2.30)2
With RA 139 9 (8.3%) 1 (3.2%) 2.72 (0.33–22.5)
COPD
Without COPD 10,502 104 (2.8%) 104 (1.5%) 1.82 (1.38–2.40)2
With COPD 842 24 (6.7%) 19 (3.9%) 1.76 (0.94–3.27)
Blindness3
Without blindness 11,237 128 (3.2%) 119 (1.7%) 1.93 (1.49–2.49)2
With blindness 107 0 (0%) 4 (7.0%) 0
Depression
Without depression 10,771 115 (3.0%) 113 (1.6%) 1.84 (1.41–2.40)2
With depression 573 13 (5.3%) 10 (3.0%) 1.78 (0.76–4.14)
Hypothyroidism
Without hypothyroidism 10,886 116 (3.0%) 118 (1.7%) 1.79 (1.38–2.32)2
With hypothyroidism 458 12 (5.4%) 5 (2.1%) 2.66 (0.92–7.69)
Obesity
Without obesity 9,905 102 (3.3%) 109 (1.8%) 1.83 (1.39–2.41)2
With obesity 2,249 26 (2.6%) 14 (1.1%) 2.34 (1.21–4.51)1
CI, confidence interval; COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel disease; OP, osteoporosis; OR, odds ratio; RA, rheumatoid
arthritis.
1Pp0.01; 2Pp0.001.
3There were 50 blind male patients in the psoriasis group, none of whom had osteoporosis.
Bold values represent statistically significant results.
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no data on the severity and duration of psoriasis or
osteoporosis. Hormonal status was similarly unavailable.
Data regarding physical activity were missing, as this
information is rarely recorded in the computerized files.
Blindness and depression are incomplete proxies for physical
activity. Many of the chronic diagnoses were associated with
psoriasis. This could be explained by clustering of chronic
illnesses (that is, a patient with one chronic illness is more
likely to be diagnosed with additional disease), or by the fact
that diseases with common risk factors are likely to be
associated with each other in a univariate analysis. Although
a potential detection bias cannot be completely excluded, we
had no reason to suspect that psoriasis patients are more
commonly referred to BMD scans.
Table 3. Stratified analysis of the association between psoriasis and osteoporosis among females (N=11,427)
Subgroups N OP in psoriasis cases (n=2,390) OP in controls (n=9,037) OR (95% CI)
All 11,427 854 (22.3%) 1,536 (20.2%) 1.13 (1.03–1.25)2
Age (years)
51–60 4,575 125 (8.4%) 235 (7.6%) 1.11 (0.88–1.39)
61–80 5,658 570 (29.6%) 1,050 (28.1%) 1.08 (0.95–1.22)
81–90 1,194 159 (39.4%) 251 (31.8%) 1.39 (1.08–1.79)2
IBD
Without IBD 11,362 841 (22.2%) 1,525(20.2%) 1.13 (1.05–1.26)1
With IBD 65 13 (44.8%) 11 (30.6%) 1.85 (0.66–5.12)
Chronic hepatitis
Without hepatitis 11,331 836 (22.2%) 1,522 (20.1%) 1.13 (1.02–1.25)1
With hepatitis 96 18 (33.3%) 14 (33.3%) 1.00 (0.42–2.36)
RA
Without RA 11,081 771 (21.5%) 1,503 (20.1%) 1.09 (0.99–1.21)
With RA 346 83 (34.9%) 33 (30.6%) 1.22 (0.74–1.99)
COPD
Without COPD 10,821 741 (21.0%) 1,422 (19.5%) 1.09 (0.99–1.22)
With COPD 295 113 (38.3%) 114 (36.7%) 1.07 (0.77–1.50)
Blindness
Without blindness 11,331 838 (22.2%) 1,514 (20.1%) 1.13 (1.03–1.25)2
With blindness 96 16 (40.0%) 22 (39.3%) 1.03 (0.45–2.37)
Depression
Without depression 10,404 709 (21.1%) 1,378 (19.6%) 1.11 (0.99–1.22)
With depression 1,023 145 (31.0%) 158 (28.4%) 1.13 (0.86–1.49)
Hypothyroidism
Without hypothyroidism 9,775 683 (21.5%) 1,284 (19.5%) 1.13 (1.02–1.26)1
With hypothyroidism 1,652 171 (26.5%) 252 (25.0%) 1.08 (0.86–1.35)
Obesity
Without obesity 8,357 620(24.8%) 1,256 (21.4%) 1.21 (1.08–1.35)3
With obesity 3,070 234 (17.6%) 280 (16.1%) 1.12 (0.92–1.36)
CI, confidence interval; COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel disease; OP, osteoporosis; OR, odds ratio; RA, rheumatoid
arthritis.
1Po0.05; 2Pp0.01; 3Pp0.001.
Bold values represent statistically significant results.
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To conclude, an association between psoriasis and
osteoporosis was observed among males, but not among
females. It would be interesting to further assess the
association in patients with psoriatic arthritis. Further
prospective studies are needed to substantiate our observa-
tion. Nevertheless, we suggest that psoriasis might be
associated with an elevated risk for osteoporosis, at least
among men, who should be advised to increase their level of
physical activity and make sure their calcium and vitamin D
intake is adequate. This study supported the claim that
psoriasis patients should be observed for development of
complex comorbidity.
It may be reasonable to suggest that patients with other
chronic inflammatory illnesses should be evaluated for
osteopenia and/or osteoporosis, as the inflammatory state,
the medications used, and the related inactivity associated
with the inflammatory disease places this population at risk
for accelerated bone mineral loss.
MATERIALS AND METHODS
Data mining techniques were used for the current case–control
study, utilizing the CHS database. CHS is the largest health provider
organization in Israel, serving a population of approximately
3,800,000 enrollees. CHS maintains a comprehensive computerized
database with continuous real-time input from pharmaceutical,
medical, and administrative computerized operating systems, facil-
itating studies of associations between chronic disease states.
Cases were patients with at least one documented diagnosis of
psoriasis in the medical records registered by a CHS physician. No
data regarding specific treatments or confirmation of the diagnosis
by a dermatologist were available. Controls were randomly selected
from the list of CHS enrollees, excluding patients with a diagnosis of
psoriasis and frequency matched to psoriasis patients on sex and age
(within eight intervals of 5–10 years, pre-defined in the database, that
is, 20–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, and 85 years
and older). Patients in the age range of 20–90 years were initially
included in this study, but as the prevalence of osteoporosis was very
low in patients younger than 51 years, we focused on those over the
age of 51 years. Data available from the database included age, sex,
ethnicity, socioeconomic status, and chronic diagnoses including
osteoporosis and diseases suspected or known as risk factors for
osteoporosis (for example, current smoking, thyroid disorders,
inflammatory bowel disease, chronic hepatitis, rheumatoid arthritis,
and chronic obstructive pulmonary disease), states associated with
decreased physical activity (depression and blindness), and obesity
(a protective factor against osteoporosis), as well as a large variety of
diagnoses (109 individual codes for chronic disease). The diagnoses
of chronic diseases, including osteoporosis, were taken from the
CHS chronic diseases registry, which is based on data withdrawn
from hospital and primary care physicians’ reports. The registry is
validated by primary physician confirmation of registered diagnoses
of chronic diseases on an on-going basis. The validity of diagnoses in
the register was previously estimated and found to be high for
important chronic diagnoses (Rennert and Peterburg, 2001). Data
regarding systemic medications for psoriasis were available as of
1998 and extracted from the central pharmaceutical database.
Person-time was not available, as the date of diagnoses is not
reliably registered in the database. Data on disease severity were
also missing. No data regarding hormonal status for women or
physical activity were available. Psoriasis patients and controls were
randomly selected from all CHS practices, without matching of
controls to patients regarding the place of residence or practice.
The proportions of patients with osteoporosis were compared
between patients with and without psoriasis by univariate analyses,
using w2 tests and t-tests for comparison of categorical and
continuous parameters between the groups, respectively. 95% CIs
for OR were calculated and rounded outward. Where the point
estimate for the OR was 0, the 95% CI was calculated using the
Cornfield method. Stratified analysis was performed to test for
confounding and effect modification. Effect modification was
identified when the P-value in Tarone’s test of homogeneity was
o0.05. Logistic regression models were used to measure the
association between psoriasis and osteoporosis in a multivariate
analysis. Variables introduced into the multivariate model were
those with P-value o0.1 in the univariate analysis. Variables
retained in the model were those with Po0.05 in the multivariate
analysis, those that changed the OR for psoriasis and osteoporosis by
Table 4. Multivariate logistic regression models for
osteoporosis among males (n=11,344, estimated
R2=0.105)
Variable OR 95% CI P-value
Psoriasis 1.35 1.04–1.75 0.024
Age (per year) 1.02 1.003–1.03 0.015
Inflammatory bowel disease 4.61 2.26–9.37 o0.001
Number of chronic diagnoses
(per additional diagnosis)
1.23 1.19–1.28 o0.001
CI, confidence interval; OR, odds ratio.
Variables introduced into the multivariate model are those with P-value
o0.1 in the univariate analysis. Variables retained in the model are those
with Po0.05 in the multivariate analysis or those that changed the OR for
psoriasis and osteoporosis by 10% or more.
Table 5. Multivariate logistic regression models for
osteoporosis among females (n=11,427, estimated
R2=0.210)
Variable OR 95% CI P-value
Psoriasis 0.90 0.80–1.00 0.049
Age (per year) 1.04 1.03–1.05 o0.001
Rheumatoid arthritis 1.31 1.46–2.40 o0.001
Depression 0.71 1.01–1.69 0.042
Hypothyroidism 0.79 0.68–0.91 o0.001
Obesity 0.34 0.29–0.39 o0.001
Number of chronic diagnoses
(per additional diagnosis)
1.29 1.26–1.32 o0.001
CI, confidence interval; OR, odds ratio.
Variables introduced into the multivariate model are those with P-value
o0.1 in the univariate analysis. Variables retained in the model are those
with Po0.05 in the multivariate analysis or those that changed the OR for
psoriasis and osteoporosis by 10% or more.
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10% or more, or those that contributed significantly to the fit of the
model. The analysis was performed separately for males and
females. In the logistic regression models, Nagelkerke R2 estimates
are reported. Statistical analysis was performed using SPSS software
(version 13) and Stata software (version 8).
The study was approved by the institutional review board of
Soroka University Medical Center, and the Declaration of Helsinki
Principles protocols were followed.
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